POLEN
OFFICIAL TITLE: PREOPERATIVE OLAPARIB ENDOMETRIAL CARCINOMA STUDY.
CLINICAL TRIAL DETAILS
A PREOPERATIVE “WINDOW-OPPORTUNITY”, MULTICENTER, PHARMACOKINETIC-PHARMACODYNAMIC STUDY TO EVALUATE THE INHIBITORY EFFECTS OF SINGLE AGENT AZD2281 (OLAPARIB), IN PATIENTS WITH EARLY-STAGE ENDOMETRIAL CARCINOMA.
THE PRIMARY OBJECTIVE OF THIS STUDY IS TO IDENTIFY, IN HUMAN TUMOUR SAMPLES, BIOMARKER CHANGES ASSOCIATED TO SHORT EXPOSURE TO AZD2281 AS POTENTIAL PREDICTORS OF ACTIVITY IN ENDOMETRIAL CARCINOMA (EC).
THIS IS AN EXPLORATORY STUDY WITH A BIOLOGICAL PRIMARY ENDPOINT. CLINICAL EFFICACY OR SAFETY ARE NOT A PRIMARY OBJECTIVE OF THE STUDY.
TUMOR TYPE
PHASE
ENDOMETRIAL
0
36
9
Spain
N
SITES
COUNTRY
STATUS
Closing
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
ESMO 2016 – DOWNLOAD THE POSTER
POLEN SITES
SPAIN
Instituto Valenciano de Oncología (IVO)
SPAIN
Hospital Clínic i Provincial de Barcelona
SPAIN
Hospital Clínico San Carlos
SPAIN
Hospital Universitario Reina Sofía
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Complejo Hospitalario Universitario de Santiago (CHUS)
SPAIN
Hospital de Granollers
SPAIN
Complejo Hospitalario Universitario A Coruña (CHUAC)
SPAIN
Hospital Álvaro Cunqueiro